IP Library Granted Patent US 11,667,889
Granted Patent B2
US 11,667,889 · App. 16/717,923 · Granted Jun 6, 2023

Methods of making human primitive ectoderm cells

Inventors: Kevin Allen D'Amour (San Diego, CA); Alan D. Agulnick (San Diego, CA); Susan Eliazer (Moraga, CA); Evert Kroon (San Diego, CA); Emmanuel E. Baetge (Encinitas, CA)
Assignee: ViaCyte, Inc.
C12N5/0606C12N5/0603C12N2500/90C12N2501/115C12N2501/155C12N2501/16C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,667,889
App. No.
16/717,923
Granted
Jun 6, 2023
Kind
B2
Abstract

This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.

Claims (16)

1. An in vitro method of producing human primitive ectoderm cells, comprising the steps of:

(a) providing a first cell culture comprising human pluripotent stem cells and a medium;

(b) providing an effective amount of activin A to the first cell culture; and

(c) culturing the first cell culture for up to about 2 hours, resulting in a second cell culture comprising human primitive ectoderm cells;

wherein the human primitive ectoderm cells express Frizzled-10 (FZD10), fibroblast growth factor 5 (FGF5), or POU domain class 5 transcription factor 1 (OCT4).

2. The method of claim 1 , wherein at least 10 ng/ml activin A is provided to the first cell culture.

3. The method of claim 1 , wherein at least 100 ng/ml activin A is provided to the first cell culture.

4. The method of claim 1 , wherein the human pluripotent stem cells are human embryonic stem cells.

5. The method of claim 1 , wherein the medium comprises serum.

6. The method of claim 5 , wherein the medium comprises less than 2% (v/v) serum.

7. The method of claim 1 , wherein an effective amount of activin B or Nodal is also provided to the first cell culture.

8. The method of claim 1 , wherein the human pluripotent stem cells are derived from a morula, an inner cell mass (ICM) of an embryo, or gonadal ridges of an embryo.

9. The method of claim 1 , wherein the second cell culture comprises at least 15% primitive ectoderm cells.

10. The method of claim 1 , wherein the second cell culture comprises at least 50% primitive ectoderm cells.

11. The method of claim 1 , wherein the second cell culture comprises at least 90% primitive ectoderm cells.

12. The method of claim 1 , wherein the medium does not comprise a serum replacement.

Assignments (2)
CHANGE OF NAME Recorded Apr 1, 2020
From: CYTHERA, INC.
To: VIACYTE, INC.
Reel/Frame 052288/0823 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2020
From: D'AMOUR, KEVIN ALLEN; AGULNICK, ALAN D.; ELIAZER, SUSAN; KROON, EVERT; BAETGE, EMMANUEL E.
To: CYTHERA, INC.
Reel/Frame 052264/0892 →
Continuity (11)
Continuation 16149999 · Oct 2, 2018
Continuation 15654624 · Jul 19, 2017
Continuation 13190390 · Jul 25, 2011
Continuation 11474211 · Jun 23, 2006
Continuation PCTUS2005024161 · Jul 8, 2005
Continuation In Part 11021618 · Dec 23, 2004
Provisional Application 60693364 · Jun 23, 2005
Provisional Application 60587942 · Jul 14, 2004
Provisional Application 60586566 · Jul 9, 2004
Provisional Application 60532004 · Dec 23, 2003
Related Publication 20200248137A1 · Aug 6, 2020